A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
Catania
Chiara
C
Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy. chiara.catania@ieo.it
Pelosi
G
G
Fazio
N
N
Biffi
R
R
Spitaleri
G
G
Noberasco
C
C
Zampino
M G
MG
Maggioni
A
A
Trifirò
G
G
Toffalorio
F
F
Vigna
P Della
PD
De Braud
F
F
De Pas
T
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004379:Duodenal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use
D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin